Emerging therapies for heart failure: Renal mechanisms and effects

Heart Failure Reviews

Volumn 17, Issue 1, 2012, Pages 1-16

  Kazory, Amir ^a   Ross, Edward A ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Adenosine; Heart failure; Renal dysfunction; Ultrafiltration; Vasopressin

Indexed keywords

ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR ANTAGONIST; BOSENTAN; CONIVAPTAN; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENDOTHELIN 1 RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; FUROSEMIDE; INOTROPIC AGENT; LIXIVAPTAN; NATRIURETIC FACTOR; NAXIFYLLINE; NESIRITIDE; PLACEBO; ROLOFYLLINE; SLV 320; TEZOSENTAN; TOLVAPTAN; TONAPOFYLLINE; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST;

ARTICLE; CONTINUOUS INFUSION; DIURESIS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; EXTRACORPOREAL ULTRAFILTRATION; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HUMAN; KIDNEY DISEASE; LIVER FUNCTION; LOADING DRUG DOSE; NATRIURESIS; NONHUMAN; PATHOPHYSIOLOGY; PHARMACOLOGICAL BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; SINGLE DRUG DOSE; ULTRAFILTRATION;

ADENOSINE A1 RECEPTOR ANTAGONISTS; CARDIO-RENAL SYNDROME; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; RECEPTORS, ENDOTHELIN; RECEPTORS, VASOPRESSIN;

EID: 84655165020     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-010-9191-5     Document Type: Article

References (70)

1. W Rosamond K Flegal K Furie A Go K Greenlund N Haase SM Hailpern M Ho V Howard B Kissela S Kittner D Lloyd-Jones M McDermott J Meigs C Moy G Nichol C O'Donnell V Roger P Sorlie J Steinberger T Thom M Wilson Y Hong 2008 American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 117 e25 146 18086926 10.1161/CIRCULATIONAHA.107.187998
2. M Gheorghiade G Filippatos 2005 Reassessing treatment of acute heart failure syndromes: the ADHERE Registry Eur Heart J 7 suppl B B13 B19 10.1093/eurheartj/sui008 (Pubitemid 40516891)
3. L Pilote K Dasgupta V Guru KH Humphries J McGrath C Norris D Rabi J Tremblay A Alamian T Barnett J Cox WA Ghali S Grace P Hamet T Ho S Kirkland M Lambert D Libersan J O'Loughlin G Paradis M Petrovich V Tagalakis 2007 A comprehensive view of sex-specific issues related to cardiovascular disease CMAJ 176 S1 44 17353516
4. H Funaya M Kitakaze K Node T Minamino K Komamura M Hori 1997 Plasma adenosine levels increase in patients with chronic heart failure Circulation 95 1363 1365 9118500 1:CAS:528:DyaK2sXisVaktbY%3D (Pubitemid 27142790)
5. V Vallon C Miracle S Thomson 2008 Adenosine and kidney function: potential implications in patients with heart failure Eur J Heart Fail 10 176 187 18242127 10.1016/j.ejheart.2008.01.010 1:CAS:528:DC%2BD1cXitVentbo%3D
6. SS Gottlieb SL Skettino A Wolff E Beckman ML Fisher R Freudenberger T Gladwell J Marshall M Cines D Bennett EB Liittschwager 2000 Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure J Am Coll Cardiol 35 56 59 10636259 10.1016/S0735-1097(99)00532-X 1:CAS:528:DC%2BD3cXptlehtw%3D%3D (Pubitemid 30061259)
7. SS Gottlieb DC Brater I Thomas E Havranek R Bourge S Goldman F Dyer M Gomez D Bennett B Ticho E Beckman WT Abraham 2002 BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy Circulation 105 1348 1353 11901047 10.1161/hc1102.105264 1:CAS:528:DC%2BD38XjtFalsL4%3D (Pubitemid 34260427)
8. V Mitrovic P Seferovic S Dodic M Krotin A Neskovic K Dickstein H de Voogd C Böcker D Ziegler M Godes R Nakov H Essers C Verboom B Hocher 2009 Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure Circ Heart Fail 2 523 531 19919976 10.1161/CIRCHEARTFAILURE. 108.798389 1:CAS:528:DC%2BD1MXhtlyqsLbL
9. HC Dittrich DK Gupta TC Hack T Dowling J Callahan S Thomson 2007 The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment J Card Fail 13 609 617 17923351 10.1016/j.cardfail.2007.08.006 1:CAS:528:DC%2BD2sXhtFentbrK (Pubitemid 47513547)
10. MM Givertz BM Massie TK Fields LL Pearson HC Dittrich 2007 CKI-201 and CKI-202 Investigators. The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance J Am Coll Cardiol 50 1551 1560 17936154 10.1016/j.jacc.2007.07.019 1:CAS:528:DC%2BD2sXhtFKisLnE (Pubitemid 47532320)
11. G Cotter HC Dittrich BD Weatherley DM Bloomfield CM O'Connor M Metra BM Massie Protect Steering Committee, Investigators, and Coordinators 2008 The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment J Card Fail 14 631 640 18926433 10.1016/j.cardfail.2008.08.010 1:CAS:528:DC%2BD1cXhtFOrtLvK
12. B Greenberg I Thomas D Banish S Goldman E Havranek BM Massie Y Zhu B Ticho WT Abraham 2007 Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo-controlled, dose-escalation study J Am Coll Cardiol 50 600 606 17692744 10.1016/j.jacc.2007.03.059 1:CAS:528:DC%2BD2sXovFyntr0%3D (Pubitemid 47198998)
13. H Funakoshi J Piuhola X Chen SM MacDonnell LL Lee DE Herrmann J Zhang J Martini TM Palmer A Sanbe J Robbins SR Houser WJ Koch AM Feldman 2006 Regulated overexpression of the A1-adenosine receptor in mice results in adverse but reversible changes in cardiac morphology and function Circulation 114 2240 2250 17088462 10.1161/CIRCULATIONAHA.106.620211 1:CAS:528:DC%2BD28XhtF2hur7N (Pubitemid 44789499)
14. P Kalk B Eggert K Relle M Godes S Heiden Y Sharkovska Y Fischer D Ziegler G-W Bielenber B Hocher 2007 The adenosine A1 receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6 nephrectomy without affecting blood pressure Br J Pharm 151 1025 1032 10.1038/sj.bjp.0707319 1:CAS:528: DC%2BD2sXot1ylsLc%3D (Pubitemid 47195534)
15. Y Liao S Takashima Y Asano M Asakura A Ogai Y Shintani T Minamino H Asanuma S Sanada J Kim H Ogita H Tomoike M Hori M Kitakaze 2003 Activation of adenosine A1 receptor attenuates cardiac hypertrophy and prevents heart failure in murine left ventricular pressure-overload model Circ Res 93 759 766 12970111 10.1161/01.RES.0000094744.88220.62 1:CAS:528:DC%2BD3sXnvFags70%3D (Pubitemid 37288671)
16. E Iwai-Kanai K Hasegawa 2004 Intracellular signaling pathways for norepinephrine- and endothelin-1-mediated regulation of myocardial cell apoptosis Mol Cell Biochem 259 163 168 15124920 10.1023/B:MCBI.0000021368.80389. b9 1:CAS:528:DC%2BD2cXisVKrsL4%3D (Pubitemid 38523294)
17. DE Kohan FT Fiedorek Jr 1991 Endothelin synthesis by rat inner medullary collecting duct cells J Am Soc Nephrol 2 150 155 1954327 1:CAS:528: DyaK38Xht1Wlurg%3D
18. WG Haynes DJ Webb 1998 Endothelin as a regulator of cardiovascular function in health and disease J Hypertens 16 1081 1098 9794709 10.1097/00004872-199816080-00001 1:CAS:528:DyaK1cXltlegtro%3D (Pubitemid 28334007)
19. H Rakugi M Nakamaru H Saito J Higaki T Ogihara 1988 Endothelin inhibits renin release from isolated rat glomeruli Biochem Biophys Res Commun 155 1244 1247 3052444 10.1016/S0006-291X(88)81273-7 1:CAS:528:DyaL1cXlvVChtLk%3D
20. EN Cozza CE Gomez-Sanchez MF Foecking S Chiou 1989 Endothelin binding to cultured calf adrenal zona glomerulosa cells and stimulation of aldosterone secretion J Clin Invest 84 1032 1035 2547837 10.1172/JCI114226 1:CAS:528:DyaK3cXhs1yitA%3D%3D (Pubitemid 19228381)
21. Y Fukuda Y Hirata H Yoshimi T Kojima Y Kobayashi M Yanagisawa T Masaki 1988 Endothelin is a potent secretagogue for atrial natriuretic peptide in cultured rat atrial myocytes Biochem Biophys Res Commun 155 167 172 2458103 10.1016/S0006-291X(88)81064-7 1:CAS:528:DyaL1cXmtVGmtbY%3D
22. D Aronson AJ Burger 2003 Neurohormonal prediction of mortality following admission for decompensated heart failure Am J Cardiol 91 245 248 12521645 10.1016/S0002-9149(02)03119-3 1:CAS:528:DC%2BD3sXotVWj (Pubitemid 36084315)
23. F Pousset R Isnard P Lechat H Kalotka A Carayon G Maistre S Escolano D Thomas M Komajda 1997 Prognostic value of plasma endothelin-1 in patients with chronic heart failure Eur Heart J 18 254 258 9043842 1:CAS:528: DyaK2sXht1yls78%3D (Pubitemid 27107587)
24. CM O'Connor WA Gattis KF Adams Jr V Hasselblad B Chandler A Frey I Kobrin M Rainisio MR Shah J Teerlink M Gheorghiade 2003 Randomized Intravenous Tezosentan Study-4 Investigators. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous Tezosentan Study (RITZ-4) J Am Coll Cardiol 41 1452 1457 12742280 10.1016/S0735-1097(03)00194-3 (Pubitemid 36543358)
25. E Kaluski I Kobrin R Zimlichman A Marmor O Krakov O Milo A Frey S Kaplan R Krakover A Caspi Z Vered G Cotter 2003 RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study J Am Coll Cardiol 41 204 210 12535809 10.1016/S0735-1097(02)02708-0 1:CAS:528: DC%2BD3sXht1Srs78%3D (Pubitemid 36092185)
26. M Packer J McMurray BM Massie A Caspi V Charlon A Cohen-Solal W Kiowski W Kostuk H Krum B Levine P Rizzon J Soler K Swedberg S Anderson DL Demets 2005 Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study J Card Fail 11 12 20 15704058 10.1016/j.cardfail.2004.05.006 1:CAS:528:DC%2BD2MXhtVOmsr8%3D (Pubitemid 40215308)
27. JJ McMurray JR Teerlink G Cotter RC Bourge JG Cleland G Jondeau H Krum M Metra CM O'Connor JD Parker G Torre-Amione DJ van Veldhuisen J Lewsey A Frey M Rainisio I Kobrin 2007 VERITAS investigators. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials JAMA 298 2009 2019 17986694 10.1001/jama.298.17. 2009 1:CAS:528:DC%2BD2sXht1yjsLjL (Pubitemid 350074798)
28. G Torre-Amione JB Young J Durand B Bozkurt DL Mann I Kobrin CM Pratt 2001 Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure Circulation 103 973 980 11181472 1:CAS:528:DC%2BD3MXit1Cqsr0%3D (Pubitemid 32183803)
29. G Torre-Amione JB Durand S Nagueh MT Vooletich I Kobrin C Pratt 2001 A pilot safety trial of prolonged (48 h) infusion of the dual endothelin-receptor antagonist tezosentan in patients with advanced heart failure Chest 120 460 466 11502644 10.1378/chest.120.2.460 1:CAS:528:DC%2BD3MXmsF2rtb8%3D (Pubitemid 32881262)
30. C Schalcher G Cotter L Reisin O Bertel I Kobrin TT Guyene W Kiowski 2001 The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure Am Heart J 142 340 349 11479476 10.1067/mhj.2001.116760 1:CAS:528:DC%2BD3MXmsV2lu7o%3D (Pubitemid 32706294)
31. G Cotter W Kiowski E Kaluski I Kobrin O Milovanov A Marmor J Jafari L Reisin R Krakover Z Vered A Caspi 2001 Tezosentan (an intravenous endothelin receptor A/B antagonist) reduces peripheral resistance and increases cardiac power therefore preventing a steep decrease in blood pressure in patients with congestive heart failure Eur J Heart Fail 3 457 461 11511432 10.1016/S1388-9842(01)00168-4 1:CAS:528:DC%2BD3MXntVSgt7k%3D (Pubitemid 32780526)
32. TF Lüscher F Enseleit R Pacher V Mitrovic MR Schulze R Willenbrock R Dietz V Rousson D Hürlimann S Philipp T Notter G Noll F Ruschitzka 2002 Heart Failure ET(A) Receptor Blockade Trial. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT) Circulation 106 2666 2672 12438291 10.1161/01.CIR.0000038497.80095.E1 (Pubitemid 35364920)
33. I Anand J McMurray JN Cohn MA Konstam T Notter K Quitzau F Ruschitzka TF Lüscher 2004 EARTH investigators. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial Lancet 364 347 354 15276394 10.1016/S0140-6736(04) 16723-8 1:CAS:528:DC%2BD2cXmtVSktbg%3D (Pubitemid 38970011)
34. G Cotter E Kaluski K Stangl R Pacher C Richter O Milo-Cotter L Perchenet I Kobrin S Kaplan M Rainisio A Frey E Neuhart Z Vered J Dingemanse G Torre-Amione 2004 The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure Eur J Heart Fail 6 601 609 15302008 10.1016/j.ejheart.2004.05.004 1:CAS:528:DC%2BD2cXmsVKmt78%3D (Pubitemid 39070514)
35. SK Prasad HJ Dargie GC Smith MM Barlow F Grothues BA Groenning JG Cleland DJ Pennell 2006 Comparison of the dual receptor endothelin antagonist enrasentan with enalapril in asymptomatic left ventricular systolic dysfunction: a cardiovascular magnetic resonance study Heart 92 798 803 16339819 10.1136/hrt.2004.049734 1:CAS:528:DC%2BD28XlvVSktrw%3D (Pubitemid 43799215)
36. N Dhaun J Goddard DE Kohan DM Pollock EL Schiffrin DJ Webb 2008 Role of endothelin-1 in clinical hypertension: 20 years on Hypertension 52 452 459 18678788 10.1161/HYPERTENSIONAHA.108.117366 1:CAS:528:DC%2BD1cXpvFKgsL8%3D
37. RW Schrier WT Abraham 1999 Hormones and hemodynamics in heart failure N Engl J Med 341 577 585 10451464 10.1056/NEJM199908193410806 1:CAS:528: DyaK1MXlvVOnsbY%3D (Pubitemid 29384167)
38. GS Francis C Benedict DE Johnstone PC Kirlin J Nicklas CS Liang SH Kubo E Rudin-Toretsky S Yusuf 1990 Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD) Circulation 82 1724 1729 2146040 10.1161/01.CIR.82.5.1724 1:STN:280:DyaK3M%2FivF2jug%3D%3D (Pubitemid 20367975)
39. JE Udelson WB Smith GH Hendrix CA Painchaud M Ghazzi I Thomas JK Ghali P Selaru F Chanoine ML Pressler MA Konstam 2001 Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure Circulation 104 2417 2423 11705818 10.1161/hc4501.099313 1:CAS:528:DC%2BD3MXpt1KhsL4%3D (Pubitemid 33108374)
40. M Gheorghiade I Niazi J Ouyang F Czerwiec J Kambayashi M Zampino 2003 Orlandi C; Tolvaptan Investigators. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure Circulation 107 2690 2696 12742979 10.1161/01.CIR.0000070422.41439.04 1:CAS:528:DC%2BD3sXjvFKjtbk%3D (Pubitemid 36667242)
41. M Gheorghiade WA Gattis CM O'Connor KF Adams Jr U Elkayam A Barbagelata JK Ghali RL Benza FA McGrew M Klapholz J Ouyang C Orlandi 2004 Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial JAMA 291 1963 1971 15113814 10.1001/jama.291.16.1963 1:CAS:528: DC%2BD2cXjs1ajsb8%3D (Pubitemid 38544277)
42. WT Abraham AA Shamshirsaz K McFann RM Oren RW Schrier 2006 Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York association functional class II and III chronic heart failure patients J Am Coll Cardiol 47 1615 1621 16630999 10.1016/j.jacc.2005.11. 071 1:CAS:528:DC%2BD28XltlCisrg%3D
43. MA Konstam M Gheorghiade JC Burnett Jr L Grinfeld AP Maggioni K Swedberg JE Udelson F Zannad T Cook J Ouyang C Zimmer 2007 Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial JAMA 297 1319 1331 17384437 10.1001/jama.297.12.1319 1:CAS:528:DC%2BD2sXjs1ejtrg%3D (Pubitemid 46513233)
44. LC Costello-Boerrigter WB Smith G Boerrigter J Ouyang CA Zimmer C Orlandi JC Burnett Jr 2006 Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human renal failure Am J Physiol Renal Physiol 290 F273 F278 16189291 10.1152/ajprenal.00195.2005 1:CAS:528:DC%2BD28XhsFKit7Y%3D (Pubitemid 43724981)
45. JE Udelson FA McGrew E Flores H Ibrahim S Katz G Koshkarian T O'Brien MW Kronenberg C Zimmer C Orlandi MA Konstam 2007 Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction J Am Coll Cardiol 49 2151 2159 17543634 10.1016/j.jacc.2007.01.091 1:CAS:528:DC%2BD2sXmtVOls7Y%3D (Pubitemid 46817812)
46. SR Goldsmith U Elkayam WH Haught A Brave W He 2008 Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study J Cardiac Fail 14 641 647 10.1016/j.cardfail.2008.06.003 1:CAS:528:DC%2BD1cXhtFOrtLvF
47. JE Udelson C Orlandi J Ouyang H Krasa CA Zimmer G Frivold WH Haught S Meymandi C Macarie D Raef P Wedge MA Konstam M Gheorghiade 2008 Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction J Am Coll Cardiol 52 1540 1545 19007589 10.1016/j.jacc.2008.08.013 1:CAS:528:DC%2BD1cXhtlahtbjK
48. EJ Topol 2005 Nesiritide-not verified N Engl J Med 353 113 116 16014879 10.1056/NEJMp058139 (Pubitemid 41058341)
49. JR Teerlink M Metra V Zacà HN Sabbah G Cotter M Gheorghiade LD Cas 2009 Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond Heart Fail Rev 14 243 253 19876734 10.1007/s10741-009-9153-y 1:CAS:528:DC%2BD1MXhtlKju73L
50. MH Drazner JE Rame LW Stevenson DL Dries 2001 Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure N Engl J Med 345 574 581 11529211 10.1056/NEJMoa010641 1:STN:280:DC%2BD3Mvos1Oqug%3D%3D (Pubitemid 32772099)
51. JD Firth AE Raine JG Ledingham 1988 Raised venous pressure: a direct cause of renal sodium retention in oedema? Lancet 1 1033 1035 2896877 10.1016/S0140-6736(88)91851-X 1:STN:280:DyaL1c3hsFOhug%3D%3D
52. SS Ali CC Olinger PA Sobotka S Bernard TG Dahle MC Bunte D Blake S Campbell AJ Boyle 2006 Enhanced sodium extraction with ultrafiltration compared to intravenous diuretics J Card Fail 12 suppl 1 S114 10.1016/j.cardfail.2006.06. 393
53. BE Jaski J Ha BG Denys S Lamba RJ Trupp WT Abraham 2003 Peripherally inserted veno-venous ultrafiltration for rapid treatment of volume overloaded patients J Card Fail 9 227 231 12815573 10.1054/jcaf.2003.28 (Pubitemid 36734320)
54. KV Liang AR Hiniker AW Williams BL Karon EL Greene MM Redfield 2006 Use of a novel ultrafiltration device as a treatment strategy for diuretic resistant, refractory heart failure: initial clinical experience in a single center J Card Fail 12 707 714 17174232 10.1016/j.cardfail.2006.08.210 (Pubitemid 44889284)
55. MR Costanzo ME Guglin MT Saltzberg ML Jessup BA Bart JR Teerlink BE Jaski JC Fang ED Feller GJ Haas AS Anderson MP Schollmeyer PA Sobotka 2007 UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure J Am Coll Cardiol 49 675 683 17291932 10.1016/j.jacc.2006.07.073 1:CAS:528:DC%2BD2sXhs1Slt7g%3D (Pubitemid 46205043)
56. HL Rogers J Marshall J Bock TC Dowling E Feller S Robinson SS Gottlieb 2008 A randomized, controlled trial of the renal effect of ultrafiltration as compared to furosemide in patients with acute decompensated heart failure J Card Fail 14 1 5 18226766 10.1016/j.cardfail.2007.09.007 1:CAS:528: DC%2BD1cXhtV2htLg%3D
57. C Bartone S Saghir SG Menon J Brosmer DJ Kereiakes W Mazur ES Chung 2008 Comparison of ultrafiltration, nesiritide, and usual care in acute decompensated heart failure Congest Heart Fail 14 298 301 19076851 10.1111/j.1751-7133.2008. 00020.x 1:CAS:528:DC%2BD1MXnsVyisQ%3D%3D
58. BA Bart A Boyle AJ Bank I Anand MT Olivari M Kraemer S Mackedanz PA Sobotka M Schollmeyer SR Goldsmith 2005 Ultrafiltration versus usual care for hospitalized patients with heart failure J Am Coll Cardiol 46 2043 2046 16325039 10.1016/j.jacc.2005.05.098 (Pubitemid 41713589)
59. MR Costanzo M Saltzberg J O'Sullivan P Sobotka 2005 Early ultrafiltration in patients with decompensated heart failure and diuretic resistance J Am Coll Cardiol 46 2047 2051 16325040 10.1016/j.jacc.2005.05.099 (Pubitemid 41713590)
60. TG Dahle D Blake SS Ali CC Olinger MC Bunte AJ Boyle 2006 Large volume ultrafiltration for acute decompensated heart failure using standard peripheral intravenous catheters J Card Fail 12 349 352 16762797 10.1016/j.cardfail.2006. 02.012 (Pubitemid 43817585)
61. BE Jaski A Romeo B Ortiz PM Hoagland M Stone D Glaser L Thomas C Walsh SC Smith Jr 2008 Outcomes of volume-overloaded cardiovascular patients treated with ultrafiltration J Cardiac Fail 14 515 520 10.1016/j.cardfail.2008.02.003 (Pubitemid 352040860)
62. A Kazory EA Ross 2009 Impact of ultrafiltration on renal function in patients with decompensated heart failure Congest Heart Fail 15 210 211 19627301 10.1111/j.1751-7133.2009.00090.x
63. Kazory A (2010) Need for a unified decision-making tool for ultrafiltration therapy in heart failure; call for action. Am Heart J (in press)
64. Kazory A (2010) Ultrafiltration does not affect certain predictors of outcome in heart failure. Int J Cardiol [Epub ahead of print]
65. A Kazory EA Ross 2009 Ultrafiltration for decompensated heart failure: renal implications Heart 95 1047 1051 19261603 10.1136/hrt.2008.160218 1:STN:280:DC%2BD1MvhsFKltA%3D%3D
66. G Cotter M Metra O Milo-Cotter HC Dittrich M Gheorghiade 2008 Fluid overload in acute heart failure-re-distribution and other mechanisms beyond fluid accumulation Eur J Heart Fail 10 165 169 18279771 10.1016/j.ejheart.2008. 01.007 (Pubitemid 351222743)
67. W Mullens Z Abrahams GS Francis G Sokos DO Taylor RC Starling JB Young WH Tang 2009 Importance of venous congestion for worsening of renal function in advanced decompensated heart failure J Am Coll Cardiol 53 589 596 19215833 10.1016/j.jacc.2008.05.068
68. TD Smilde DJ van Veldhuisen G Navis AA Voors HL Hillege 2006 Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction Circulation 114 1572 1580 17015793 10.1161/CIRCULATIONAHA.105.610642 (Pubitemid 44547427)
69. K Kalantar-Zadeh SD Anker TB Horwich GC Fonarow 2008 Nutritional and anti-inflammatory interventions in chronic heart failure Am J Cardiol 101 89E 103E 18514634 10.1016/j.amjcard.2008.03.007 1:CAS:528:DC%2BD1cXotlCqtrY%3D
70. GM Mutlu JI Sznajder 2005 Mechanisms of pulmonary edema clearance Am J Physiol Lung Cell Mol Physiol 289 L685 L695 16214819 10.1152/ajplung.00247.2005 1:CAS:528:DC%2BD2MXht1Cnt73O (Pubitemid 41504397)